Lys Therapeutics and Inserm Transfert Sign a Three-Year Agreement for Joint Research on Stroke and Multiple Sclerosis

Lys Therapeutics, a French biotech company developing innovative treatments for neurovascular and neurodegenerative diseases, announces today that they have signed a three-year research agreement with Inserm Transfert, acting for Inserm and the University of Caen-Normandy. This collaboration contract stems from the licensing agreement signed by Lys Therapeutics to obtain exclusive worldwide rights on the portfolio of patents protecting the company's drug candidates. This research collaboration aims to generate new preclinical data in order to support the clinical trials of Lys Therepeutics' flagship molecule, the monoclonal antibody Glunozumab®, for the treatment of neurovascular disorders such as stroke and neurodegenerative diseases, including multiple sclerosis.

(Photo : Lys Therapeutics)

Worldwide Exclusive License for Lys Therapeutics

Lys Therapeutics holds the exclusive worldwide rights for patents protecting the Company's drug candidates for all applications and all territories. This agreement was negotiated with Inserm Transfert, extended today by a three-year research agreement. This collaboration will result in a base of new preclinical data allowing the preparation of the future stages of clinical development of the Company.

A world-renowned institute and exceptional high-resolution imagery to decipher the brain

As part of the collaboration, several significant players contribute to developing this research:

• PhIND (Physiopathology and Imagery of Neurological Disorders, UMR-S 1237), the mixed research institute of Inserm and University of Caen-Normandy, directed by Pr. Denis Vivien,
• BB@C Institute (Blood and Brain @ Caen-Normandy Institute) from Inserm, University of Caen-Normandy and Caen-Normandy University Hospital,
• Cyceron, a unique platform for high-resolution biomedical imagery, especially in the field of neurosciences, whose founding members include CEA, CNRS, Inserm, University of Caen-Normandy, Caen-Normandy University Hospital, the François Baclesse Center, as well as the Normandy Region and the Caen-La-Mer urban community.

"Being able to collaborate with research teams, clinicians and key opinion leaders with such experience represent a unique opportunity for Lys Therapeutics » explains Manuel Blanc, CEO and co-founder of the company, adding "after a successful first phase of development, this collaboration is a new acceleration for the company. It will allow us to continue demonstrating the worldwide exclusivity of the mechanism of action as well as the unprecedented therapeutic efficacy of our monoclonal antibody Glunozumab®."

"Through this collaboration, we hope to continue to develop the clinical potential for research coming out of our laboratories. We are very pleased about the partnership with Lys Therapeutics, which will allow us to truly move forward to satisfy the medical needs of patients with serious neurological disorders," explains Pr. Denis Vivien, University Professor-Hospital Practitioner, Director of PhIND and Scientific Director of the Blood and Brain @ Caen-Normandy Institute.

"Inserm Transfert is proud to have contributed to the signature of this collaboration agreement with Lys Therapeutics, biotechnology company spin-off from Inserm and University of Caen-Normandy. This agreement will allow fundamental research to find practical applications that serve human health and patients," declared Pascale Augé, Chairman of the executive management board for Inserm Transfert.

"Collaborating with Lys Therapeutics meets the purpose of Cyceron: to gather the best of fundamental and entrepreneurial research in a single place, with the support of its technology platform for world-class, biomedical and multimodal imagery. Long-term, Cyceron is happy to provide technologies and skills to Lys Therapeutics aiming to contribute to this ambitious drug development project through a translational approach benefitting patients with neurological disorders," explains Benoit Haelewyn, Director of Cyceron.